Search results
Results from the WOW.Com Content Network
The usual dosage of etifoxine (as the hydrochloride salt) is 150 to 200 mg per day in divided doses of 50 to 100 mg two to three times per day (e.g., 50 mg–50 mg–100 mg). [ 2 ] [ 7 ] [ 6 ] [ 18 ] [ 1 ] [ 19 ] [ 20 ] It is taken for a few days to a few weeks, but no longer than 12 weeks.
Topiramate, sold under the brand name Topamax among others, is a medication used to treat epilepsy and prevent migraines. [9] It has also been used in alcohol dependence and essential tremor. [9]
capsule cap. capiat: let him take (let the patient take) c.m. cras mane: tomorrow morning c.m.s. cras mane sumendus: to be taken tomorrow morning c̄, c. cum: with (usually written with a bar on top of the c) cib. cibus: food c.c. cum cibo: with food [or] cubic centimetre
Dosage forms (also called unit doses) are pharmaceutical drug products presented in a specific form for use. They contain a mixture of active ingredients and inactive components ( excipients ), configured in a particular way (such as a capsule shell) and apportioned into a specific dose .
Miltefosine, sold under the trade name Impavido among others, is a medication mainly used to treat leishmaniasis and free-living amoeba infections such as Naegleria fowleri and Balamuthia mandrillaris. [4]
A capsule is a gelatinous envelope enclosing the active substance. Capsules can be designed to remain intact for some hours after ingestion in order to delay absorption. They may also contain a mixture of slow and fast release particles to produce rapid and sustained absorption in the same dose.
The opposite of an indication is a contraindication, [4] a reason to withhold a certain medical treatment because the risks of treatment clearly outweigh the benefits. In the United States, indications for prescription drugs are approved by the FDA. Indications are included in the Indications and Usage section of the Prescribing Information.
The most well-known compound in this class is fingolimod (FTY720), which was the first oral disease-modifying therapy approved for the treatment of relapsing-remitting MS. These drugs have the ability to modulate the G-protein coupled S1P receptors.